BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

Search i

Search help

  • Enter one or more search terms in the search field. Upper and lower case are not relevant.
  • As soon as you have entered three letters in the search field, various search words will be suggested from which you can choose one.
  • If you are searching for a certain group of words, put these words in double quotes. The hits will then contain the words in the order you entered, e.g. "medicines for children".
  • Multiple search terms can also be combined with the Boolean operators AND and OR. When using the operator AND, the results contain the intersection of all search terms. When using the operator OR, the hits contain one of the search terms or only individual search terms. The result set is therefore significantly larger. Please note that these operators must be written in capital letters.
  • If you receive a (too) large number of hits as a result of your search, you can narrow it down by using filters. These filter options appear to the left of the search results and are subdivided into:

    • category (e.g. safety of medicinal products, medical devices, code systems)
    • format (e.g. download, risk information, DHPCs)
    • time interval (e.g. last 30 days, older than ...)
  • Selected filters can be removed individually or all at once ("Show all results").
  • By default, search results are sorted by relevance, but they can also be sorted chronologically ("Latest entries first" or "Oldest entries first").

Enter search term

819 results

Results per page: 10 20 30

Dear Doctor Letter (Rote-Hand-Brief) on Revlimid® (lenalidomide): Occurrence of venous and arterial thromboembolic events PDF, 1MB, File is accessible Date: 27. December 2010 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: lenalidomide

Important safety-relevant information on the occurrence of venous and arterial thromboembolic events associated with Revlimid® (lenalidomide).

Dear Doctor Letter (Rote-Hand-Brief) on Thelin® (sitaxentan): Withdrawal from the market PDF, 108KB, File is accessible Date: 27. December 2010 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: sitaxentan

Withdrawal of Thelin® (sitaxentan) from the market due to unpredictable progression of serious hepatic impairment.

Rote-Hand-Brief on Revlimid® PDF, 1MB, File is accessible Date: 21. December 2010 Topics: Pharmakovigilanz Type: Download

Active substance: lenalidomide

Rote-Hand-Brief on Thelin® PDF, 125KB, File is accessible Date: 21. December 2010 Topics: Pharmakovigilanz Type: Download

Active substance: sitaxentan

SSRIs, venlafaxine and mirtazapine and the risk of Persistent Pulmonary Hypertension in Neonates (PPHN) - Final SPC and PL wording agreed by the PhVWP in March 2010 PDF, 32KB, File is accessible Date: 20. December 2010 Topics: Pharmakovigilanz Type: Download

SSRIs, venlafaxine and mirtazapine and the risk of Persistent Pulmonary Hypertension in Neonates (PPHN)

Fluoxetine and the risk of Congenital Malformations - Final SPC and PL wording Agreed by the PhVWP in March 2010 PDF, 13KB, File is accessible Date: 20. December 2010 Topics: Pharmakovigilanz Type: Download

Fluoxetine and the risk of Congenital Malformations

Rote-Hand-Brief on Dianeal®, Extraneal®, Nutrineal® PDF, 65KB, File is accessible Date: 20. December 2010 Topics: Pharmakovigilanz Type: Download

peritoneal dialysis solution

Rote-Hand-Brief on Nplate® PDF, 2MB, File is accessible Date: 15. December 2010 Topics: Pharmakovigilanz Type: Download

Active substance: romiplostim

Dear Doctor Letter (Rote-Hand-Brief) on Nplate® (romiplostim): Possible risk of thrombotic/thromboembolic events PDF, 2MB, File is accessible Date: 15. December 2010 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: romiplostin

Important safety-relevant information for medical experts regarding the revised dose adjustment in patients with immune thrombocytopenic purpura (ITP) as well as the warnings for administration in ITP patients with hepatic impairment.

Thelin® (sitaxentan): intended withdrawal from the market Date: 14. December 2010 Topics: Pharmakovigilanz Type: Risk information

Active substance: sitaxentan

The pharmaceutical company Pfizer has informed the BfArM that it intends to withdraw Thelin® (sitaxentan) from the market.